Differential Phosphorylation, Desensitization, and Internalization of α 1A−Adrenoceptors Activated by Norepinephrine and Oxymetazoline
Molecular Pharmacology, ISSN: 0026-895X, Vol: 83, Issue: 4, Page: 870-881
2013
- 48Citations
- 62Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations48
- Citation Indexes46
- CrossRef46
- 46
- Policy Citations2
- Policy Citation2
- Captures62
- Readers62
- 62
Article Description
Loss of response on repetitive drug exposure (i.e., tachyphylaxis) is a particular problem for the vasoconstrictor effects of medications containing oxymetazoline (OXY), an α 1-adrenoceptor (AR) agonist of the imidazoline class. One cause of tachyphylaxis is receptor desensitization, usually accompanied by phosphorylation and internalization. It is well established that α 1A-ARs are less phosphorylated, desensitized, and internalized on exposure to the phenethylamines norepinephrine (NE), epinephrine, or phenylephrine (PE) than are the α 1B and α 1D subtypes. However, here we show in human embryonic kidney-293 cells that the low-efficacy agonist OXY induces G protein–coupled receptor kinase 2–dependent α 1A-AR phosphorylation, followed by rapid desensitization and internalization (∼40% internalization after 5 minutes of stimulation), whereas phosphorylation of α 1A-ARs exposed to NE depends to a large extent on protein kinase C activity and is not followed by desensitization, and the receptors undergo delayed internalization (∼35% after 60 minutes of stimulation). Native α 1A-ARs from rat tail artery and vas deferens are also desensitized by OXY, but not by NE or PE, indicating that this property of OXY is not limited to recombinant receptors expressed in cell systems. The results of the present study are clearly indicative of agonist-directed α 1A-AR regulation. OXY shows functional selectivity relative to NE and PE at α 1A-ARs, leading to significant receptor desensitization and internalization, which is important in view of the therapeutic vasoconstrictor effects of this drug and the varied biologic process regulated by α 1A-ARs.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0026895X24036903; http://dx.doi.org/10.1124/mol.112.082313; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84875467192&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23364786; https://linkinghub.elsevier.com/retrieve/pii/S0026895X24036903; https://dx.doi.org/10.1124/mol.112.082313; https://molpharm.aspetjournals.org/content/83/4/870
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know